SPIRE SIGN IN Register

Media Coverage

Spire's six most recent media appearances.

5G in emerging markets: opportunities and constraints
5G in emerging markets: opportunities and constraints
Spire offices in 4 SEA countries supported Korea’s ICT Business Part...
Business opportunities in Singapore’s sunshine plan
Spire connects SEA countries with Korean ICT Businesses
2020 US Electoral Battle
Spire helps facilitate Korea’s ICT Business Partnership in SEA

Singapore’s biomedical efforts enjoy another win

30 March 2007 
TODAY 

Singapore’s biomedical efforts enjoy another win

Synopsis

Biologics firm Lonza broke ground at its second biologics manufacturing plant in Singapore yesterday, the latest in a string of announcements regarding the local biomedical industry.

Singapore’s biologics industry has managed to attract four commercial scale investments in the last two years.

The global biologics industry is expected to hit an annual value of US$70 billion by 2010.

However, the group managing director of Spire Research and Consulting, Mr Leon Perera, believes that biologics manufacturing would not outdo pharmaceuticals for “a very long time to come”.

“I don’t expect it will grow exponentially because the number of biologics manufacturing projects around the world is still somewhat limited,” he said. “FDA approval cycles are still quite long.”

The biomedical industry requires merely a small number of skilled employees to run the facility, thus the potential to create jobs is also limited.

“You can have a lot of capital investments, you could have spin-offs in supporting industries but not employ huge numbers of people,” Mr Perera added.

“Biomedical can’t replace the job creation function of electronics.”

Back to Top

Back to Home
BTBTBTBTBTBT